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Background. Walking speed (WS) predicts mortality. However, it is unclear if decline in WS increases prior to death. 
We examined whether (a) WS declined faster in persons who died during the follow-up compared with those who 
remained alive and (b) adding change in WS to a model including age, sex, and baseline WS improved prediction of 
mortality.
Methods. Data are from 4,016 participants of the Dijon center of the Three-City study (France), aged 65–85 years. 
Fast WS (FWS) was measured up to five times over a 12-year period. Mortality was ascertained until 2012.
Results. Linear mixed models using a backward time scale showed that FWS declined faster in 908 participants who 
died during the follow-up (annual change = −0.031 m/s) than in those who survived (−0.021 m/s), corresponding to a dif-
ference of −0.009 (95% confidence interval = −0.013 to −0.005) m/s. Compared with “normal” change in FWS (annual 
change ≥−0.04 m/s), “substantial” decline (<−0.08 m/s) was associated with a 1.4-fold greater risk of mortality (hazards 
ratio = 1.40, confidence interval = 1.02–1.92) and small decline (−0.08 to −0.04 m/s) with a 1.2-fold greater risk (hazards 
ratio = 1.18, confidence interval = 0.89–1.57). The net reclassification index when adding these categories of change in 
FWS to the model adjusted for age, sex, and baseline FWS was 19.0% (0.6, 36.8%).
Conclusion. Participants who died during the follow-up had a steeper decline in FWS than the others. Both baseline 
FWS and FWS decline predict mortality.
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WALKING speed (WS) is a robust predictor of mortal-ity (1,2). A pooled analysis concluded that age, sex, 
and WS predicted mortality, as well as a more complete set 
of variables (age, sex, diseases, body mass index, systolic 
blood pressure, and hospitalization) (2). Most studies, with 
a few notable exceptions where change in WS over 1 or 2 
years was analyzed (3–5), have examined whether a sin-
gle WS measure predicts subsequent mortality. It remains 
unclear whether decline in WS is associated with risk of 
mortality.
Investigation into the cognitive trajectories of older 
adults provides evidence of a rapid decline in cognitive 
function preceding death (6,7). Underlying conditions 
(dementia and stroke) may play a role in some persons, 
but the accumulation of brain pathology or other biologic 
changes may also be involved (7,8). The extent to which 
terminal decline exists for physical functioning remains 
little explored (8,9). Using up to five measures of fast WS 
(FWS) over 12 years in individuals aged 65–85 years, 
we examined whether (a) FWS declined more rapidly in 
persons who died during follow-up compared with those 
who remained alive and (b) adding FWS decline to a model 
including age, sex, and baseline FWS improved prediction 
of mortality.
Methods
Study Population
The 3C study is a prospective cohort study conducted 
in three French cities (Bordeaux, Dijon, and Montpellier) 
(10). Electoral rolls were used to invite community dwell-
ers aged 65 years or more (recruitment rate = 37%). This 
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study is based on data collected in Dijon (n = 4931), where 
a specific study on physical functioning was conducted.
After baseline (wave 0, 1999–2001), participants were 
seen approximately every 2 years; 6 waves of data collection 
have taken place until 2012 in addition to the baseline assess-
ment. At each wave (except wave 3 that consisted in a ques-
tionnaire), participants up to 85 years of age were invited to 
the study center for a clinical examination, whereas older 
participants were seen at home; however, to maximize par-
ticipation, all participants were offered the opportunity of 
being seen at home. The study protocol was approved by the 
Ethical Committee of the University Hospital of Kremlin-
Bicêtre; all participants gave informed consent.
Measures
WS was measured at baseline and at 4 (2003–2004, 
wave 2), 8 (2007–2008, wave 4), 10 (2009–2010, wave 5), 
and 12 years (2011–2012, wave 6)  later, among partici-
pants up to 85 years of age who attended the study center 
(Figure 1). WS was measured at the study center using two 
photoelectric cells connected to a chronometer placed in a 
corridor 6 m apart. Two tests were carried out; participants 
were first asked to walk at their “usual” speed and then 
at “fast” speed, ie, as fast as they could without running. 
For wave 6, a home measure was added using portable 
photoelectric cells (n = 202); WS was measured over a 
6 m distance in 89% cased and between 3.5 and 5 m in 11% 
cases. WS was computed as 6 m divided by time taken 
to complete the test in seconds. In a test–retest study, the 
intraclass correlation coefficient (SE) was 0.84 (0.02) for 
usual and 0.92 (0.02) for FWS (11). Given similar results 
for both measures, the higher reliability of FWS, and a 
markedly larger decline over time of FWS compared with 
usual WS (12), all results are presented using the former 
measure.
Mortality was available until 2012. Participants were 
contacted at each wave, and relatives and personal physi-
cians of those who could not be reached were contacted to 
obtain information on their vital status.
Figure 1. Flow chart.
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Information on other covariates (disability, falls, soci-
odemographic, anthropometric, health behaviors, dis-
eases, depressive symptoms, and cognition) is presented as 
Supplementary Material.
Statistical Methods
We excluded from the analyses participants with health 
conditions associated with marked gait impairment (recent 
hip fracture, parkinsonism, dementia, and disabling stroke; 
see Supplementary Table 1 for sensitivity analyses includ-
ing these participants). Participants’ baseline characteristics 
are presented as a function of vital status at the end of fol-
low-up and sex-specific tertiles of baseline FWS. Two sets 
of analyses were performed.
1. to compare change in fWS among deceased and non-
deceased participants, change in FWS preceding death 
or end of the follow-up was estimated using linear mixed 
models with the intercept and slope as random effects 
and a backward time scale (7,13). In contrast to a positive 
scale starting at baseline, this approach does not assume 
that FWS trajectories continue after death. The starting 
time point (t = 0) was (a) date of wave 6 for participants 
with FWS data at wave 6, (b) date of death for participants 
whose FWS was assessed at the last wave before death, (c) 
the midpoint between the date at which FWS was last meas-
ured and date of next wave for other participants. The time 
scale was defined backward from this starting point until 
the first FWS measure.
Vital status was included as a covariate in the linear 
mixed model to examine change in FWS as a function of 
vital status. First we modeled FWS as a function of vital 
status, age at t = 0, sex, time (in years), vital status × time, 
and age (at t = 0) × time (Model 1). The regression coef-
ficient of the vital status × time interaction corresponds 
to the mean difference in annual change in FWS between 
deceased and nondeceased participants.
We then included additional covariates associated with 
FWS and vital status (Model 2). For time-invariant vari-
ables (age, sex, height, education, smoking, and homocyst-
eine), we included their main effect and interaction with 
time. Time-varying variables (body mass index, physical 
activity, coronary/peripheral artery disease, diabetes, mini-
mental state examination score, lipid-lowering, antihyper-
tensive, and psychotropic medications) were entered as 
main effects; in further analyses, we included their interac-
tions with time.
We investigated whether delay between the last FWS 
measure and death or end of follow-up had an effect on the 
estimate of change in FWS by repeating the analyses in par-
ticipants for whom a FWS measure was available in the last 
2 or 4 years before death or end of follow-up.
FWS was not available for all participants at each wave. 
Reasons for missingness included death, age greater than 85 
years, conditions associated with marked gait impairment, 
home interviews, and loss to follow-up. To investigate the 
influence of missing data, we used multiple imputation 
(Supplementary Methods).
2. to assess whether adding change in fWS to a model 
including age, sex, and baseline fWS improved the 
prediction of mortality, we estimated annual change in FWS 
using ordinary least squares regression for participants with 
FWS measures at the first 2 waves (5,14). Standardized 
measures of baseline FWS and change in FWS were entered 
successively in an age- and sex-adjusted Cox proportional 
hazards model. In supplementary analyses, we entered FWS 
at wave 2 and checked whether adding change between 
baseline and wave 2 or baseline FWS improved prediction 
of mortality.
We repeated this analysis using categories of change in 
FWS based on two different definitions based on a distribu-
tion-based method (15): (a) categories previously defined 
for usual WS (16) were “substantial” decline, less than 
−0.08 m/s; “small” decline, −0.08 to −0.04 m/s; and “nor-
mal” change, more than or equal to −0.04 m/s; (b) catego-
ries based on distribution of FWS in our population were 
“substantial” decline, less than −0.5 × SD of baseline FWS 
(<−0.14 m/s); “small” decline, −0.05 SD ≤ change <−0.02 
SD (−0.14 to −0.06 m/s); and “normal” change, more than 
or equal to −0.02 SD (≥−0.06 m/s). Compared with a con-
tinuous measure of change, an advantage of these cutoffs 
is that they may be more easy to implement in the clinical 
setting to identify persons with marked decline in whom 
preventive strategies may be useful.
To assess improvement in the model’s predictive value, 
we used an extension of the net reclassification improve-
ment (NRI) for survival analysis that offers a simple way to 
assess improvement in risk reclassification in the context of 
comparing two models (17); 95% confidence intervals (CI) 
were computed using a bootstrap approach.
In order to examine whether change in FWS predicts 
both short- and long-term mortalities, we repeated these 
analyses by stratifying the follow-up period in two periods: 
the first 4 years following the last FWS measure and the 
years following this 4-year period.
Results
Sample Description
Among 4,285 participants eligible at baseline, 
4,016 participants with at least 1 FWS measure during 
follow-up compose the study population (Figure  1). 
Participants without FWS measures (n = 269) were 
older and more disabled at baseline (p < .001). Of the 
4,016 participants, 908 died during the follow-up, 498 
reached their 86th birthday during the study period, 
1,250 stopped coming to the study center or dropped 
out from the study, and 256 developed conditions that 
strongly affected gait. Of participants included in the 
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analysis, 664 (16.5%) contributed to five waves of 
data collection, 575 (14.3%) to four, 570 (14.2%) to 
three, 898 (22.4%) to two, and 1,309 (32.6%) to one. 
Participants with one FWS measure were older (75.7 vs 
72.2 years, p < .0001) and walked slower (1.43 vs 1.58 
m/s, p < .0001) at baseline. Table  1 presents baseline 
characteristics of study participants. Participants with 
slower baseline FWS were more likely to be older, 
women, less educated, shorter, less physically active, 
have higher body mass index, greater number of pack-
years of smoking, and more health problems.
Change in fWS in Deceased and Nondeceased 
Participants
Table 2 presents adjusted fixed effects for the model of 
annual change in FWS before death or end of follow-up 
Table 2. Fixed Effects for Multilevel Models of Change in Fast Walking Speed Before Death or End of Follow-up
Fixed Effects
Model 1 Model 2*
Estimate (95% CI) p Estimate (95% CI) p
Intercept† 1.551 (1.537, 1.567) <.0001 1.581 (1.560, 1.603) <.0001
Sex (women vs men) −0.241 (−0.257, −0.226) <.0001 −0.192 (−0.215, −0.170) <.0001
Age (centered at 80 y), per 10-y increment) −0.152 (−0.174, −0.131) <.0001 −0.152 (−0.174, −0.131) <.0001
Vital status (dead vs alive) −0.090 (−0.113, −0.067) <.0001 −0.074 (−0.097, −0.051) <.0001
Time (annual change) −0.021 (−0.022, −0.020) <.0001 −0.020 (−0.022, −0.018) <.0001
Time × age −0.006 (−0.009, −0.002) .002 −0.006 (−0.010, −0.003) .0004
Time × vital status −0.009 (−0.013, −0.005) <.0001 −0.009 (−0.014, −0.005) <.0001
Notes: CI = confidence interval. *Adjusted for sex, age, vital status, education, height, smoking ≥20 pack-years, homocysteine, time, time × age, time × vital 
status, time × education, time × height, time × smoking ≥20 pack-years, time × homocysteine, time-dependent variables (body mass index, physical activity, coronary/
peripheral artery disease, antihypertensive drugs, diabetes, lipid-lowering drugs, mini-mental state examination score, psychotropic drugs).
†In model 1, the intercept corresponds to the average walking speed at the end of follow-up for men alive and aged 80 y. In model 2, the intercept corresponds to 
the average walking speed at the end of follow-up for men alive and aged 80 y, with primary school level, body mass index = 25 kg/m2, height = 165 cm, physically 
active, smoking <20 pack-years, no health conditions, mini-mental state examination = 30, homocysteine = 14 µmol/L.
Table 1. Baseline Characteristics of the Participants by Vital Status at the End of the Follow-up and Baseline Sex-Specific  
Tertiles of Fast Walking Speed (FWS)
Characteristics* Overall† (n = 4,016)
Vital Status†
P‡
Baseline FWS§
P¶Alive (n = 3,108) Dead (n = 908) T1|| (n = 1,256) T2 (n = 1,258) T3 (n = 1,197)
Age (M, SD) 73.4 (4.7) 72.7 (4.3) 75.7 (4.9) <.0001 75.3 (4.7) 73.2 (4.5) 71.7 (4.2) <.0001
Women 61.7 65.8 47.2 <.0001 60.8 65.5 58.6 <.0001
Primary school or less 34.7 34.6 34.8 .93 44.2 34.2 24.2 <.0001
BMI ≥30 kg/m2 13.5 12.9 15.4 .007 20.3 12.3 7.7 <.0001
Height, cm (M, SD) 161.7 (8.8) 161.4 (8.6) 163.0 (9.2) .79 160.48 (8.9) 161.26 (8.7) 163.53 (8.5) <.0001
Low physical activity 23.5 22.1 29.3 .002 30.3 20.7 19.5 <.0001
Grams of alcohol/wk (M, SD) 12.1 (13.7) 11.5 (13.3) 14.4 (15.6) .60 12.1 (14.3) 11.5 (13.2) 12.8 (13.6) .10
Smoking ≥20 pack-years 16.5 14.3 24.6 <.0001 17.4 16.0 16.2 .01
Coronary artery disease 10.2 8.4 16.3 <.0001 13.9 9.1 7.4 <.0001
Peripheral artery disease 3.2 2.1 6.9 <.0001 4.8 2.3 2.5 <.0001
Antihypertensive treatment 47.2 44.2 57.0 <.0001 57.1 45.2 39.0 <.0001
Diabetes mellitus 7.6 6.7 10.2 .003 9.9 6.7 6.1 <.0001
Homocysteine, µmol/L (M, SD) 14.9 (5.6) 14.5 (4.9) 16.3 (7.2) <.0001 15.8 (5.9) 14.56 (5.1) 14.3 (5.6) <.0001
Lipid-lowering drugs 33.6 34.3 30.5 .17 34.2 35.3 31.3 <.0001
MMSE score (M, SD) 27.5 (1.9) 27.5 (1.9) 27.2 (1.9) .02 27.0 (2.4) 27.6 (1.8) 27.8 (1.7) <.0001
Psychotropic drugs 25.5 24.0 28.5 .02 33.4 24.0 18.6 <.0001
Depressive symptoms# 13.1 12.4 14.1 .39 18.1 11.4 9.5 <.0001
NSAIDs 14.9 15.1 14.5 .72 19.5 14.4 10.6 <.0001
Disability** 5.0 3.6 9.0 <.0001 9.7 3.4 1.6 <.0001
Fall in the preceding year 16.9 16.2 19.9 .003 20.1 17.7 12.7 <.0001
Walking speed, m/s (M, SD) 1.5 (0.3) 1.6 (0.3) 1.5 (0.3) <.0001 1.2 (0.2) 1.5 (0.1) 1.9 (0.2) <.0001
Notes: ADL = activities of daily living; IADLs = instrumental activities of daily living; T = tertile; M = mean; SD = standard deviation; BMI = body mass 
index; MMSE = mini-mental state examination; NSAIDs = nonsteroidal anti-inflammatory drugs. *Percents unless otherwise stated.
†4016 participants with ≥1 FWS measure during follow-up.
‡Analysis of covariance (continuous variables) or Cochran-Mantel-Haenszel chi-square test (categorical variables) age adjusted and sex adjusted.
§3711 participants with baseline FWS.
||Cutoffs: men: T1: ≤1.50 m/s; T2: 1.51–1.82 m/s; T3: >1.82 m/s; women: T1: ≤1.30 m/s; T2: 1.31–1.50 m/s; T3: >1.50 m/s.
¶Linear regression or analysis of covariance with continuous walking speed as the outcome, age- and sex adjusted.
#Center for Epidemiological Studies-Depression score ≥17 for men or ≥23 for women.
**Disabled for mobility and IADLs/ADLs. Missing for 133 (relation with vital status) and 124 (relation with walking speed) subjects.
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(n  = 4016). For nondeceased men aged 80 years at the 
end of follow-up, the average annual change in FWS was 
−0.021 m/s (95% CI: −0.022 to −0.020). Men who died 
during follow-up had a more pronounced decline (−0.031 
m/s, CI: −0.035 to −0.026), corresponding to a difference 
of −0.009 m/s (CI: −0.013 to −0.005; Table 2, Model 1). 
This difference was not affected by age (p age × time × 
vital status = 0.16). Figure  2 shows the predicted mean 
FWS change for deceased and nondeceased men aged 80 
years at the end of follow-up (Model 1); the difference in 
FWS between both groups increased as death or end of 
follow-up approached.
After adjustment for sociodemographic, anthropomet-
ric, lifestyle, and health variables, the difference in FWS 
change between deceased and nondeceased participants 
was similar to the one estimated in Model 1 (−0.009 m/s, 
CI: −0.014 to −0.005; Table 2, Model 2). Including interac-
tions between time-varying variables and time did not alter 
these findings (−0.008 m/s, CI: −0.013 to −0.004).
The difference in FWS change between deceased and 
nondeceased participants was also evident when restricting 
the analytic sample to those with data on FWS available in 
the last 2 years before death or end of follow-up (n = 1,573, 
178 deaths: −0.009 m/s, CI: −0.015 to −0.002). This was 
also true for those with data in the last 4 years (n = 2,386, 
390 deaths: −0.009 m/s, CI: −0.014 to −0.004).
Sensitivity analyses.—Compared with the −0.009 
m/s difference in annual FWS change from main analy-
ses, analyses including participants with health condi-
tions associated with marked gait impairment showed 
a similar difference (−0.010 m/s, CI: −0.014 to −0.006; 
Supplementary Table  1), as well as analyses based on 
multiple imputation (−0.008 m/s, CI: −0.013 to −0.003; 
Supplementary Table 2).
Decline in fWS as a Predictor of Mortality
These analyses are based on 2,094 participants with FWS 
measures at the 2 first waves, among whom 308 (14.7%) died. 
The mean baseline FWS was 1.580 (SD = 0.299) m/s, and 
mean annual change in FWS was −0.023 (SD = 0.065) m/s. 
Table 3 shows hazards ratio (HR) for models adjusted succes-
sively for baseline FWS and change in FWS. In an age- and 
sex-adjusted model, an increase of one SD in FWS at baseline 
was associated with a 21% lower mortality (HR = 0.79, CI: 
0.70–0.90). When change in FWS was added, both baseline 
FWS (HR = 0.71, CI: 0.62–0.82) and change in FWS (HR = 
0.80, CI: 0.71–0.90) independently predicted death. The NRI 
when adding change in FWS to the model including age, sex, 
and baseline FWS was 27.9% (CI: 9.3, 44.5%).
Analysis using categories of change in FWS defined 
by Kwon and colleagues (16) for usual WS showed that, 
compared with normal change (≥−0.04 m/s, n = 1,359, 184 
deaths), substantial decline (<−0.08 m/s, n = 322, 58 deaths) 
was associated with a 1.4-fold greater risk of mortality (HR = 
1.40, CI: 1.02–1.92) and small decline (−0.08 to −0.04 m/s, 
n = 413, 66 deaths) with a 1.2-fold greater risk (HR = 1.18, 
CI: 0.89–1.57; Table 3). The NRI when adding these cat-
egories of change in FWS to the model adjusted for age, 
sex, and baseline FWS was 19.0% (0.6, 36.8%). Analyses 
using alternative categories of change defined based on the 
distribution of FWS in our population (small decline: −0.14 
to −0.06 m/s, n = 403, 67 deaths; substantial decline: <−0.14 
m/s, n = 97, 21 deaths; normal change: ≥−0.06, n = 1,594, 
220 deaths) showed similar trends. The NRI when adding 
these categories of change in FWS to the model adjusted 
for age, sex, and baseline FWS was 16.3% (−2.6, 33.3%). 
There was no interaction (p > .67) between baseline FWS 
and categories of change in FWS, suggesting that the effect 
of change in FWS was evident at all levels of baseline FWS.
Analyses stratified by follow-up period showed that 
baseline FWS was associated both with short- and long-
term mortalities, whereas the association with change in 
FWS was more pronounced in the first 4 years of follow-
up, particularly when categories of change in FWS were 
used (Table 3).
Supplementary analysis (Supplementary Table 3) showed 
that in a model including age, sex and FWS at wave 2, base-
line FWS or change in FWS between baseline and wave 2 
were not associated with mortality and did not improve the 
predictive value of the model (all NRI not significantly dif-
ferent from 0).
Discussion
Summary of the Results
In this large cohort study of community-dwelling elderly per-
sons aged 65–85 years with up to five assessments of FWS over 
12 years, participants who died during the study experienced 
a steeper decline in FWS before death compared with those 
who remained alive. We examined whether this difference had 
Figure  2. Predicted trajectories of fast walking speed in deceased (solid 
line) and nondeceased (dashed line) men aged 80 years at the end of the follow-
up and their 95% confidence intervals (dotted lines).
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clinical implications and found that adding change in FWS to a 
survival model including age, sex, and baseline FWS improved 
the predictive performances of the model.
What this study Adds
There is robust evidence of an association between 
slower WS, when measured once, with subsequent mortality 
(1,2,18), but less is known about change in WS preceding 
death (1,2). Previous studies have examined the associa-
tion between change in WS and risk of mortality (3–5,9) 
and showed that higher decline was associated with higher 
risk of mortality. Apart from one exception (9), these stud-
ies were smaller than the present one, and change in WS 
was examined over a maximum of 2 years while participants 
were followed for mortality over at most 8 years (3–5). In 
the Health ABC study (n = 2,364) (9), WS was assessed 
three times over 2 years and the follow-up period for mortal-
ity was of 10 years. Another study (n = 690) showed lower 
baseline scores and larger decline in a composite score of 
lower extremity function in 470 participants who died dur-
ing a 12-year follow-up period (19). This study has several 
strengths: it is based on a large cohort of community-dwell-
ing older adults; FWS was measured up to five times over 12 
years; many potential confounders were assessed throughout 
follow-up. In addition to survival analyses similar to those 
previously carried out in other studies, we also used linear 
mixed models with a backward time scale to model change 
in FWS; this approach has been used to examine trajecto-
ries of health indicators preceding adverse outcomes (7,13), 
including motor (8) and cognitive decline (7).
Baseline FWS and change in FWS had independent effects 
on the risk of death. Although there was both a short- and 
a long-term association between baseline FWS and death, 
our findings suggest that change in FWS had a more pro-
nounced effect on the risk of death in the short term than 
in the long term. In addition, FWS at wave 2, which results 
from baseline FWS and decline in FWS between waves 1 
and 2, appears to be a good predictor of upcoming death, and 
baseline FWS or change in FWS between baseline and wave 
2 did not improve prediction of mortality compared with a 
model including FWS at wave 2 only. This result is compara-
ble with findings from one study showing that 1-year change 
in FWS does not provide additional prognostic information 
for dependence in activities of daily living beyond that avail-
able based on the last FWS measure (20). Our findings have 
three clinical implications: first, repeated assessments of 
FWS may help identify persons particularly at risk of adverse 
outcomes, even among those with normal baseline FWS; sec-
ond, the advent of marked decline in FWS is suggestive of a 
higher risk of death in the relatively near future; third, if FWS 
is repeatedly measured, the last and more recent measure is 
sufficient to predict mortality. The identification of persons 
with marked motor decline should lead to assess their health 
status in order to identify possible causes and implement the 
corresponding therapeutic strategies.
As shown previously (12) and also found in the 3C Study, 
there is a greater decline and interindividual variability in 
fast than usual WS. This led us to use FWS for the analyses 
as it is expected that differences in decline across groups 
of people are more easily detectable by clinicians for this 
measure. There is no cutoff available for meaningful change 
Table 3. Prediction of Mortality According to Baseline Fast Walking Speed (FWS) and Change in FWS
Model*
Baseline FWS
Change in 
FWS (Cont)
Change in FWS (categorical)†
Normal Change Small Decline Substantial Decline
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Full follow-up period (n = 2,094; 308 deaths)
 M1: age, sex, baseline FWS (Cont) 0.79 (0.70, 0.90) — — — —
 M2: M1 + change in FWS (Cont) 0.71 (0.62, 0.82) 0.80 (0.71, 0.90) — — —
 M3: M1 + change in FWS (Cat1)† 0.76 (0.66, 0.86) — 1.00 (ref) 1.18 (0.89, 1.57) 1.40 (1.02, 1.92)
 M3: M1 + change in FWS (Cat2)‡ 0.75 (0.66, 0.85) — 1.00 (ref) 1.24 (0.94, 1.65) 1.94 (1.22, 3.11)
Four first years of follow-up (n = 2,094; 93 deaths)
 M1: age, sex, baseline FWS (Cont) 0.81 (0.65, 1.03) — — — —
 M2: M1 + change in FWS (Cont) 0.72 (0.56, 0.92) 0.77 (0.63, 0.94) — — —
 M3: M1 + change in FWS (Cat1)† 0.74 (0.58, 0.94) — 1.00 (ref) 1.53 (0.93, 2.54) 2.05 (1.19, 3.53)
 M3: M1 + change in FWS (Cat2)‡ 0.74 (0.59, 0.94) — 1.00 (ref) 1.62 (1.00, 2.63) 2.49 (1.15, 5.39)
Excluding the four first years of follow-up (n = 1,921; 215 deaths)
 M1: Age, sex, baseline FWS (Cont) 0.78 (0.67, 0.91) — — — —
 M2: M1 + change in FWS (Cont) 0.71 (0.60, 0.83) 0.81 (0.71, 0.93) — — —
 M3: M1 + change in FWS (Cat1)† 0.77 (0.65, 0.90) — 1.00 (ref) 1.05 (0.74, 1.49) 1.17 (0.79, 1.73)
 M3: M1 + change in FWS (Cat2)‡ 0.75 (0.64, 0.88) — 1.00 (ref) 1.10 (0.77, 1.56) 1.73 (0.96, 3.11)
Notes: CI = confidence interval; Cont = continuous; Cat = categorical; M = model; HR = hazards ratio; ref = reference. *Continuous variables are standardized: 
the HR for baseline FWS corresponds to an increment of 0.299 m/s; the HR for FWS change corresponds to an increase in 1 y change FWS of 0.065 m/s.
†Categorical definition 1 (Cat1) of annual change in FWS: substantial decline: <−0.08 m/s; small decline: −0.08 to −0.04 m/s; normal: ≥−0.04 m/s.
‡Categorical definition 2 (Cat2) of annual change in FWS: substantial decline: <−0.14 m/s; small decline: −0.06 to −0.14 m/s; normal: ≥−0.06 m/s.
§p value comparing the predictive values of M2/M3 with M1.
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in FWS, so we used the cutoffs proposed by Kwon and col-
leagues (16) for usual WS to identify clinically meaning-
ful change and they appeared to be relevant with respect to 
mortality in our study. The alternative method that we used 
to define categories of change in FWS based on cut-points 
derived from a distribution-based method showed slightly 
stronger associations with mortality, although CIs were 
larger due to the small number of participants with substan-
tial decline. Further research is thus needed to replicate these 
analyses and define cutoffs for meaningful change for FWS.
Potential Mechanisms
Walking is a complex activity involving several (eg, mus-
culoskeletal, pulmonary, neurological, and cardiovascular) 
systems (2). Mechanisms underlying the WS-mortality asso-
ciation are likely to be multifactorial. First, cardiovascular 
health is a common determinant of WS and longevity. WS 
has been associated with several cardiovascular outcomes or 
risk factors, including cardiovascular death (18), stroke (21), 
diabetes (22), homocysteine (23), hypertension (11), arterial 
stiffness (24), coronary artery calcification (25), and intima-
media thickness (26). In this study, after adjustment for car-
diovascular risk factors and diseases, the association between 
WS decline and mortality remained robust. Nevertheless, WS 
decline could reflect underlying cardiovascular conditions not 
taken into account, and imperfect measurement of cardiovas-
cular risk factors may have resulted in residual confounding. 
The number of events did not allow us to perform analyses 
by cause of death, which may be useful in future studies. 
Second, slow WS is a risk factor for dependency (27), which 
predicts mortality (28) and could represent an intermediate 
factor. Third, WS decline may be an early indicator of loss of 
muscle strength (12,29) or sarcopenia (30) and frailty (31), 
which predict mortality (31). Inflammation plays a role in 
frailty (32,33), and increased levels of inflammatory markers 
have been shown to be associated with slower WS (34,35) 
and higher risk of mortality (36,37). Thus, inflammatory pro-
cesses could be involved in this association (38).
Investigation into cognitive trajectories of older adults 
provides evidence of a more market decline in cognitive 
function in the years before death, irrespective of premor-
bid cognitive level (6,7). When this rapid decline in cog-
nitive function is gradual in the years preceding death, it 
is referred to “terminal decline,” and when this decline is 
interrupted by precipitous acceleration of the decline, it is 
referred to “terminal drop” (39). The extent to which a sim-
ilar phenomenon exists for physical functioning has been 
little explored (8). Because participants who died during 
the follow-up were more likely to reach their 86th birthday 
during the follow-up, FWS measures were more likely to 
be missing in the few years preceding death; therefore, we 
could not distinguish whether there was a gradual decline 
(terminal decline) or an abrupt change (terminal drop) 
before death usually assessed using a quadratic term for 
change over time or change point models (39), but we were 
only able to study change in FWS as a linear function of 
time due to those missing FWS before death. Higher reso-
lution data with shorter intervals between WS measures are 
needed to address this question.
In order to assess whether the greater FWS decline 
observed in the years preceding death was confounded 
by cognitive decline, analyses were adjusted for cognitive 
status (mini-mental state examination) modeled as a time-
varying variable, and the association remained unchanged. 
Declines in cognitive function and FWS before death 
might represent two different aspects of the same process 
and suggest that different physiological functions exhibit 
faster decline in the years preceding death. The parallel-
ism between declines in cognitive and physical functioning 
is important and further research is required to assess the 
extent to which this finding extends to other physical meas-
ures (strength and balance).
Study Limitations
The main limitation of our analyses is related to partici-
pants who dropped out during follow-up. One of the main 
reasons was that FWS was not measured in participants 
who were interviewed at home at all waves. Nevertheless, 
other measures (eg, disability, falls, and cognition) linked 
to functional health were assessed in these persons and 
used in analyses based on multiple imputation that yielded 
results that were in agreement with our main conclusion. 
In addition, FWS was not measured after 85 years, so we 
cannot test whether our findings on change in FWS can be 
extended to older ages. Finally, participants who accepted 
to participate to the study were community-dwelling, 
well-functioning older people. Although this is likely to 
lead to an underestimation of the incidence of events such 
as death, it has been shown that the relation between an 
exposure and mortality during follow-up is less likely to 
be biased (40).
Conclusion
This study shows that FWS decline is greater in individu-
als aged 65–85 years who will die in the next few years 
than in those who remain alive and that FWS change pre-
dicts mortality independently of baseline FWS. Therefore, 
repeated FWS measures may be clinically useful in elderly 
people and may help identify persons with marked motor 
decline in whom health assessments and preventive strate-
gies may be useful. Future research should measure FWS 
on several occasions with shorter intervals between meas-
ures, to detect when FWS trajectories of participants at 
higher risk of mortality deviate from those at lower risk.
Supplementary Material
Supplementary material can be found at: http://biomedgerontology.
oxfordjournals.org/
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